atenolol has been researched along with Kidney Failure, Chronic in 25 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among maintenance dialysis patients with hypertension and left ventricular hypertrophy, atenolol-based antihypertensive therapy may be superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations." | 9.19 | Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. ( Abraham, TN; Agarwal, R; Pappas, MK; Sinha, AD; Tegegne, GG, 2014) |
| "A supervised administration of atenolol following hemodialysis effectively and safely controls hypertension in chronic hemodialysis patients." | 9.09 | Supervised atenolol therapy in the management of hemodialysis hypertension. ( Agarwal, R, 1999) |
| "Atenolol was started on an alternate day, 37." | 5.31 | Long-term control of hypertension in dialysis patients by low dose atenolol. ( Hadjiconstantinou, VE; Hadjiyannakos, DK; Karras, SM; Mentzikof, DG; Noussias, CV; Vlassopoulos, DA, 2002) |
| " For both enantiomers, the volume of distribution decreases and the half-life increases in the uraemic rats." | 5.29 | Stereoselective pharmacokinetics of atenolol in the rat: influence of aging and of renal failure. ( Belpaire, FM; Bogaert, MG; De Smet, F; Rosseel, MT; Vermeulen, AM, 1993) |
| "Post hoc analysis of the Hypertension in Hemodialysis Patients Treated With Atenolol or Lisinopril (HDPAL) trial." | 5.20 | Aortic Stiffness, Ambulatory Blood Pressure, and Predictors of Response to Antihypertensive Therapy in Hemodialysis. ( Agarwal, R; Georgianos, PI, 2015) |
| "Among maintenance dialysis patients with hypertension and left ventricular hypertrophy, atenolol-based antihypertensive therapy may be superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations." | 5.19 | Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. ( Abraham, TN; Agarwal, R; Pappas, MK; Sinha, AD; Tegegne, GG, 2014) |
| "A supervised administration of atenolol following hemodialysis effectively and safely controls hypertension in chronic hemodialysis patients." | 5.09 | Supervised atenolol therapy in the management of hemodialysis hypertension. ( Agarwal, R, 1999) |
| "In long-term hemodialysis patients, treating hypertension using home BP measurements may improve well-being." | 2.82 | Treating hypertension in hemodialysis improves symptoms seemingly unrelated to volume excess. ( Agarwal, R, 2016) |
| "Aortic stiffness and left ventricular hypertrophy (LVH) are predictors of mortality in hemodialysis (HD) patients." | 2.71 | Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. ( Adda, H; Guerin, AP; London, GM; Marchais, SJ; Metivier, F; Pannier, B, 2003) |
| "100 hypertensive patients with chronic renal failure (initial serum creatinine 200-400 mumol/l." | 2.67 | Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. ( Chanard, J; Durand, D; el Esper, N; Fournier, A; Godin, M; Goldfarb, B; Hannedouche, T; Landais, P; Mignon, F; Suo, JM, 1994) |
| "Losartan treatment lowered significantly LPO in kidney tissue after 2 and 4 weeks of treatment compared with untreated and atenolol-treated animals and induced the decrease of excretion of isoprostanes in urine at the end of the study." | 1.32 | Oxidative stress status in kidney tissue after losartan and atenolol treatment in experimental renal failure. ( Aunapuu, M; Kullissaar, T; Ots, M; Pechter, U; Riispere, Z; Vihalemm, T; Zilmer, K; Zilmer, M, 2004) |
| "Atenolol was started on an alternate day, 37." | 1.31 | Long-term control of hypertension in dialysis patients by low dose atenolol. ( Hadjiconstantinou, VE; Hadjiyannakos, DK; Karras, SM; Mentzikof, DG; Noussias, CV; Vlassopoulos, DA, 2002) |
| "In conclusion, ESRD patients taking atenolol or captopril are needed to be frequently monitored for blood potassium levels and it would be advisable to avoid these drugs to control hypertension in ESRD patients, especially, when scheduled for renal transplantation." | 1.30 | Effect of antihypertensives on plasma potassium in end stage renal disease: a retrospective study. ( Gaur, A; Kaushik, S; Kher, V; Tripathi, M, 1997) |
| " For both enantiomers, the volume of distribution decreases and the half-life increases in the uraemic rats." | 1.29 | Stereoselective pharmacokinetics of atenolol in the rat: influence of aging and of renal failure. ( Belpaire, FM; Bogaert, MG; De Smet, F; Rosseel, MT; Vermeulen, AM, 1993) |
| " 3 Without dialysis treatment, the apparent plasma half-life of atenolol was greatly increased (73." | 1.26 | Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis. ( Aubert, P; Baglin, A; Decourt, S; Domart, M; Flouvat, B; Goupil, A; Potaux, L, 1980) |
| " Dosing recommendations are suggested for patients with renal failure to take account of the effects of renal function on atenolol kinetics." | 1.26 | Atenolol kinetics in renal failure. ( Holmes, BF; Hood, D; McAinsh, J; Smith, S; Warren, D, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (28.00) | 18.7374 |
| 1990's | 6 (24.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 5 (20.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Georgianos, PI | 2 |
| Agarwal, R | 5 |
| Zhou, H | 1 |
| Sim, JJ | 1 |
| Shi, J | 1 |
| Shaw, SF | 1 |
| Lee, MS | 1 |
| Neyer, JR | 1 |
| Kovesdy, CP | 1 |
| Kalantar-Zadeh, K | 1 |
| Jacobsen, SJ | 1 |
| Hoot, NR | 1 |
| Benitez, JG | 1 |
| Palm, KH | 1 |
| Sinha, AD | 1 |
| Pappas, MK | 1 |
| Abraham, TN | 1 |
| Tegegne, GG | 1 |
| London, GM | 1 |
| Marchais, SJ | 1 |
| Guerin, AP | 1 |
| Metivier, F | 1 |
| Adda, H | 1 |
| Pannier, B | 1 |
| Aunapuu, M | 2 |
| Pechter, U | 2 |
| Arend, A | 1 |
| Suuroja, T | 1 |
| Ots, M | 2 |
| Riispere, Z | 1 |
| Vihalemm, T | 1 |
| Kullissaar, T | 1 |
| Zilmer, K | 1 |
| Zilmer, M | 1 |
| Arrizabalaga, P | 1 |
| Montoliu, J | 1 |
| Martinez Vea, A | 1 |
| Andreu, L | 1 |
| López Pedret, J | 1 |
| Revert, L | 1 |
| Salahudeen, AK | 1 |
| Wilkinson, R | 1 |
| McAinsh, J | 2 |
| Bateman, DN | 1 |
| Flouvat, B | 1 |
| Decourt, S | 1 |
| Aubert, P | 2 |
| Potaux, L | 1 |
| Domart, M | 1 |
| Goupil, A | 1 |
| Baglin, A | 1 |
| Holmes, BF | 1 |
| Smith, S | 1 |
| Hood, D | 1 |
| Warren, D | 1 |
| Hannedouche, T | 1 |
| Landais, P | 1 |
| Goldfarb, B | 1 |
| el Esper, N | 1 |
| Fournier, A | 1 |
| Godin, M | 1 |
| Durand, D | 1 |
| Chanard, J | 1 |
| Mignon, F | 1 |
| Suo, JM | 1 |
| Belpaire, FM | 1 |
| Rosseel, MT | 2 |
| Vermeulen, AM | 1 |
| De Smet, F | 1 |
| Bogaert, MG | 2 |
| Bacon, NC | 1 |
| Tripathi, M | 1 |
| Kaushik, S | 1 |
| Gaur, A | 1 |
| Kher, V | 1 |
| Salhanick, SD | 1 |
| Wax, PM | 1 |
| Vlassopoulos, DA | 1 |
| Mentzikof, DG | 1 |
| Hadjiyannakos, DK | 1 |
| Noussias, CV | 1 |
| Karras, SM | 1 |
| Hadjiconstantinou, VE | 1 |
| Faller, J | 1 |
| Hess, B | 1 |
| Guédon, J | 1 |
| Lucsko, M | 1 |
| Chaignon, M | 1 |
| Christiaens, M | 1 |
| Verpooten, GA | 1 |
| De Broe, ME | 1 |
| Hepp, A | 1 |
| Maisch, B | 1 |
| Raff, U | 1 |
| Hayduk, K | 1 |
| Schiffl, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hypertension in Hemodialysis Patients[NCT00582114] | Phase 3 | 200 participants (Actual) | Interventional | 2005-08-31 | Terminated (stopped due to Stopped by data safety monitoring board) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cardiovascular events were counted by subject and included the following: myocardial infarction (MI), stroke, hospitalization for congestive heart failure (CHF), hospitalized angina, arrhythmias, cardiac arrest, coronary revascularization and heart valve replacement. Adverse events reported are those during the course of 12 months of participation in the trial. All serious adverse events were adjudicated by R.A. and A.D.S. who were masked to the drug assignment at the time of adjudication. The duration of participation in the study per subject, which according to the trial design could be up to 12 months, was determined. The cardiovascular event rate was calculated by treatment group assignment. Incidence rate ratio (IRR) by treatment was then determined along with the 95% confidence intervals (95% CIs). As a post hoc analysis, we also determined the narrower definition of cardiovascular events per group that included MI, stroke, CHF, or cardiovascular death. (NCT00582114)
Timeframe: 1 yr
| Intervention | events/100 patient-years (Number) | |||
|---|---|---|---|---|
| Incidence rate, cardiovasular events | Incidence rate, combined MI, stroke, CHF, CV death | Incidence rate, congest heart failure | Incidence rate, all-cause hospitalizations | |
| Atenolol | 24.6 | 13.5 | 6.2 | 89.9 |
| Lisinopril | 58 | 31 | 20.2 | 144.3 |
The primary outcome of the study was the average reduction in left ventricular mass indexed for body surface area from baseline to 1 year. A mixed model was used with left ventricular mass index (LVMI) as the outcome variable. Fixed effects were indicator variables for time, treatment and their interaction. Random effect was subject and statistical inference was made using the maximum likelihood estimator. No imputation was made for missing data. (NCT00582114)
Timeframe: Baseline, 6 months, 12 months
| Intervention | g/m^2 (Mean) | |
|---|---|---|
| LVMI Change from baseline, 6 months | LVMI Change from baseline, 12 months | |
| Atenolol | -8.4 | -21.5 |
| Lisinopril | -3.4 | -15.1 |
1 review available for atenolol and Kidney Failure, Chronic
| Article | Year |
|---|---|
Systolic and diastolic hypertension among patients on hemodialysis: Musings on volume overload, arterial stiffness, and erythropoietin.
Topics: Atenolol; Diastole; Epoetin Alfa; Erythropoietin; Female; Follow-Up Studies; Humans; Hypertension; I | 2019 |
6 trials available for atenolol and Kidney Failure, Chronic
| Article | Year |
|---|---|
Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Double-Blind Method; Early Termination of Clinical T | 2014 |
Aortic Stiffness, Ambulatory Blood Pressure, and Predictors of Response to Antihypertensive Therapy in Hemodialysis.
Topics: Adult; Aged; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure Monitoring, Ambulatory; Early | 2015 |
Treating hypertension in hemodialysis improves symptoms seemingly unrelated to volume excess.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Blood Volume; Body Weight; Female; Humans; Hypert | 2016 |
Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients.
Topics: Adult; Antihypertensive Agents; Aortic Diseases; Arteriosclerosis; Atenolol; Blood Pressure; C-React | 2003 |
Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure.
Topics: Acebutolol; Adolescent; Adult; Aged; Atenolol; Blood Pressure; Body Weight; Enalapril; Female; Human | 1994 |
Supervised atenolol therapy in the management of hemodialysis hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Atenolol; | 1999 |
18 other studies available for atenolol and Kidney Failure, Chronic
| Article | Year |
|---|---|
β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atenolol; Bisoprolol; Carvedilol; Cause of Dea | 2021 |
Hemodynamically unstable: accidental atenolol toxicity?
Topics: Abdominal Pain; Adult; Antihypertensive Agents; Atenolol; Bradycardia; Female; Gastrointestinal Agen | 2013 |
Ultrastructural changes in the remnant kidney (after 5/6 nephrectomy) glomerulus after losartan and atenolol treatment.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atenolol; Ba | 2003 |
Oxidative stress status in kidney tissue after losartan and atenolol treatment in experimental renal failure.
Topics: Animals; Atenolol; Disease Models, Animal; Kidney; Kidney Cortex; Kidney Failure, Chronic; Losartan; | 2004 |
Increase in serum potassium caused by beta-2 adrenergic blockade in terminal renal failure: absence of mediation by insulin or aldosterone.
Topics: Adult; Aged; Aldosterone; Atenolol; Female; Humans; Insulin; Kidney Failure, Chronic; Male; Middle A | 1983 |
Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
Topics: Adult; Atenolol; Creatinine; Humans; Kidney Failure, Chronic; Kinetics; Peritoneal Dialysis; Periton | 1984 |
Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.
Topics: Adult; Aged; Atenolol; Half-Life; Humans; Kidney Failure, Chronic; Kinetics; Male; Middle Aged; Prop | 1980 |
Atenolol kinetics in renal failure.
Topics: Adult; Aged; Atenolol; Biological Availability; Blood Pressure; Creatinine; Heart Rate; Humans; Kidn | 1980 |
Stereoselective pharmacokinetics of atenolol in the rat: influence of aging and of renal failure.
Topics: Aging; Animals; Atenolol; Injections, Intravenous; Kidney; Kidney Failure, Chronic; Male; Metabolic | 1993 |
Hospital-acquired hyperkalaemia.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Ateno | 1997 |
Effect of antihypertensives on plasma potassium in end stage renal disease: a retrospective study.
Topics: Adolescent; Adult; Antihypertensive Agents; Atenolol; Captopril; Female; Humans; Hypertension; Kidne | 1997 |
Treatment of atenolol overdose in a patient with renal failure using serial hemodialysis and hemoperfusion and associated echocardiographic findings.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Charcoal; Drug Overdose; Electrocardiography; Emergenc | 2000 |
Long-term control of hypertension in dialysis patients by low dose atenolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Blood P | 2002 |
[Medicamentous kidney protection in type 2 diabetic patients--is cheaper also more economical? A model calculation for Swiss health care].
Topics: Adult; Antihypertensive Agents; Atenolol; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus, Ty | 2002 |
[beta-blockers in hypertension with renal failure].
Topics: Acebutolol; Adrenergic beta-Antagonists; Adult; Atenolol; Diuretics; Drug Therapy, Combination; Fema | 1978 |
Plasma levels of atenolol after haemodialysis in patients with end stage renal disease.
Topics: Atenolol; Humans; Kidney Failure, Chronic; Propanolamines; Renal Dialysis | 1979 |
[Comparative studies with propranolol, verapamil and atenolol in hypertensive dialysis patients].
Topics: Atenolol; Humans; Hypertension, Renal; Kidney Failure, Chronic; Propanolamines; Propranolol; Renal D | 1977 |
Correlation of blood pressure in end-stage renal disease with platelet cytosolic free-calcium concentration.
Topics: Adult; Atenolol; Blood Platelets; Blood Pressure; Calcium; Cytosol; Female; Humans; Hypertension, Re | 1990 |